PMID- 22349672
OWN - NLM
STAT- MEDLINE
DCOM- 20121024
LR  - 20211021
IS  - 1432-1971 (Electronic)
IS  - 0172-0643 (Linking)
VI  - 33
IP  - 5
DP  - 2012 Jun
TI  - Effects of inhaled iloprost on congenital heart disease with Eisenmenger 
      syndrome.
PG  - 744-8
LID - 10.1007/s00246-012-0204-0 [doi]
AB  - Identification of the pathophysiology associated with Eisenmenger syndrome has 
      led to the evaluation of targeted therapies. Iloprost is one such targeted 
      therapy used for patients with Eisenmenger syndrome. This study aimed to assess 
      the efficacy and safety of iloprost used for patients with Eisenmenger syndrome. 
      In this study, 12 patients with Eisenmenger syndrome (mean age, 33.2 +/- 12.1 
      years; 75% female) started receiving iloprost 10 mug/dose administered six times a 
      day. Of the 12 patients, 9 were classified as New York Heart Association (NYHA) 
      functional class 3, and three were categorized as functional class 4. Changes in 
      6-min walk distance, NYHA functional class, oxygen saturation at resting, and 
      results after the 6-min walk test were checked, as well as changes in right 
      ventricle diameter and pulmonary arterial pressure shown by echocardiography. The 
      distance during a 6-min walk increased from 255.8 +/- 120.4 to 349.4 +/- 134.7 m (p = 
      0.013), and 10 patients improved their NYHA functional class by one grade (p = 
      0.007). The mean resting oxygen saturation (SpO(2)) increased from 80.6 +/- 14.2 to 
      84.9 +/- 13.0% (p = 0.040), and after the 6-min walk test, it increased from 63.8 +/- 
      22.9 to 68.8 +/- 21.5% (p = 0.007). The mean right ventricle diameter during the 
      diastolic phase changed from 53.7 +/- 4.8 to 51.4 +/- 3.9 mm (p = 0.068), and the 
      mean pulmonary arterial pressure changed from 62.8 +/- 13.7 to 58.9 +/- 11.7 mmHg (p 
      = 0.059). Neither death nor critical adverse effects occurred for any patients. 
      Mild headache and dyspnea were common reports during the iloprost treatments. No 
      patients stopped the therapy due to these adverse effects. Iloprost is well 
      tolerated and appears to be beneficial in the management of patients with 
      Eisenmenger syndrome.
FAU - Yang, Song I
AU  - Yang SI
AD  - Division of Pediatric Cardiology, Cardiovascular Center, Gil Hospital, Gachon 
      University, 1198 Kuwol-dong, Namdong-gu, Incheon 405-760, Korea.
FAU - Chung, Wook Jin
AU  - Chung WJ
FAU - Jung, Sung Hwan
AU  - Jung SH
FAU - Choi, Deok Young
AU  - Choi DY
LA  - eng
PT  - Journal Article
DEP - 20120218
PL  - United States
TA  - Pediatr Cardiol
JT  - Pediatric cardiology
JID - 8003849
RN  - 0 (Vasodilator Agents)
RN  - JED5K35YGL (Iloprost)
SB  - IM
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Adult
MH  - Cardiac Catheterization
MH  - Echocardiography
MH  - Eisenmenger Complex/diagnostic imaging/*drug therapy/physiopathology
MH  - Exercise Tolerance/physiology
MH  - Female
MH  - Humans
MH  - Iloprost/*administration & dosage
MH  - Male
MH  - Oximetry
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
MH  - Vasodilator Agents/*administration & dosage
EDAT- 2012/02/22 06:00
MHDA- 2012/10/25 06:00
CRDT- 2012/02/22 06:00
PHST- 2011/10/03 00:00 [received]
PHST- 2011/11/23 00:00 [accepted]
PHST- 2012/02/22 06:00 [entrez]
PHST- 2012/02/22 06:00 [pubmed]
PHST- 2012/10/25 06:00 [medline]
AID - 10.1007/s00246-012-0204-0 [doi]
PST - ppublish
SO  - Pediatr Cardiol. 2012 Jun;33(5):744-8. doi: 10.1007/s00246-012-0204-0. Epub 2012 
      Feb 18.